Barter PJ, Brewer HB Jr., Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(2):160–7. https://doi.org/10.1161/01.atv.0000054658.91146.64.

Article  CAS  PubMed  Google Scholar 

Silva MC, Janssens AC, Hofman A, Witteman JC, van Duijn CM. Cholesteryl ester transfer protein gene and coronary heart disease mortality: the Rotterdam study. J Am Geriatr Soc. 2007;55(9):1483–4. https://doi.org/10.1111/j.1532-5415.2007.01275.x.

Article  PubMed  Google Scholar 

Nelson AJ, Sniderman AD, Ditmarsch M, et al Cholesteryl Ester transfer protein inhibition reduces major adverse cardiovascular events by lowering apolipoprotein B levels. Int J Mol Sci. 2022;23(16). . https://doi.org/10.3390/ijms23169417

Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22. https://doi.org/10.1056/NEJMoa0706628.

Article  CAS  PubMed  Google Scholar 

Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99. https://doi.org/10.1056/NEJMoa1206797.

Article  CAS  PubMed  Google Scholar 

Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 2017;376(20):1933–42. https://doi.org/10.1056/NEJMoa1609581.

Article  PubMed  Google Scholar 

HPS3/TIMI55-REVEAL Collaborative Group, Bowman L, Hopewell JC, et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017;377(13):1217–27. https://doi.org/10.1056/NEJMoa1706444.

Article  Google Scholar 

Sammons E, Hopewell JC, et al. The HPS3/TIMI55-REVEAL Collaborative Group, Writing Committee, Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J. 2022;43(14):1416–24. . https://doi.org/10.1093/eurheartj/ehab863

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386(9992):452–60. https://doi.org/10.1016/S0140-6736(15)60158-1.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672–8. https://doi.org/10.1038/s41591-022-01936-7.

Article  CAS  PubMed  Google Scholar 

Kastelein JJP, Ditmarsch M, Hsieh A, et al. A Drug-Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy Volunteers. Am J Cardiovasc Drugs. 2025;25(5):693–702. https://doi.org/10.1007/s40256-025-00740-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ballantyne CM, Ditmarsch M, Kastelein JJ, et al. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023;17(4):491–503. https://doi.org/10.1016/j.jacl.2023.05.098.

Article  PubMed  Google Scholar 

Sarraju A, Brennan D, Hayden K, et al. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;405(10491):1757–68. https://doi.org/10.1016/S0140-6736(25)00721-4.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025;393(1):51–61. https://doi.org/10.1056/NEJMoa2415820.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026. https://doi.org/10.1038/s41591-025-04179-4.

Article  PubMed  Google Scholar 

Araujo B, Arrighini GS, Queiroga F, et al. Efficacy and safety of obicetrapib in patients with dyslipidemia: an updated meta-analysis of randomized controlled trials. Am J Prev Cardiol. 2025;24:101303. https://doi.org/10.1016/j.ajpc.2025.101303.

Article  PubMed  PubMed Central  Google Scholar 

Matteucci A, Di Fusco SA, Bonanni M, et al. Comparative efficacy and safety of obicetrapib vs bempedoic acid on top of statin therapy: A network meta-analysis. J Clin Lipidol. 2026. https://doi.org/10.1016/j.jacl.2026.02.018.

Article  PubMed  Google Scholar 

Nurmohamed NS, Ditmarsch M, Kastelein JJP. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res. 2022;118(14):2919–31. https://doi.org/10.1093/cvr/cvab350.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nicholls SJ, Nelson AJ, Ray KK, et al. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025;86(14):1046–56. https://doi.org/10.1016/j.jacc.2025.07.056.

Article  CAS  PubMed  Google Scholar 

Albers JJ, Tollefson JH, Wolfbauer G, Albright RE Jr. Cholesteryl ester transfer protein in human brain. Int J Clin Lab Res. 1992;21(3):264–6. https://doi.org/10.1007/BF02591657.

Article  CAS  PubMed  Google Scholar 

Yamada T, Kawata M, Arai H, Fukasawa M, Inoue K, Sato T. Astroglial localization of cholesteryl ester transfer protein in normal and Alzheimer’s disease brain tissues. Acta Neuropathol. 1995;90(6):633–6. https://doi.org/10.1007/BF00318577.

Article  CAS  PubMed  Google Scholar 

Balazs Z, Panzenboeck U, Hammer A, et al. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J Neurochem. 2004;89(4):939–50. https://doi.org/10.1111/j.1471-4159.2004.02373.x.

Article  CAS  PubMed  Google Scholar 

Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299(23):2777–88. https://doi.org/10.1001/jama.299.23.2777.

Article  CAS  PubMed  Google Scholar 

Barzilai N, Atzmon G, Derby CA, Bauman JM, Lipton RB. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology. 2006;67(12):2170–5. https://doi.org/10.1212/01.wnl.0000249116.50854.65.

Article  CAS  PubMed  Google Scholar 

Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA. 2003;290(15):2030–40. https://doi.org/10.1001/jama.290.15.2030.

Article  CAS  PubMed  Google Scholar 

Lythgoe C, Perkes A, Peterson M, et al. Population-based analysis of cholesteryl ester transfer protein identifies association between I405V and cognitive decline: the Cache County Study. Neurobiol Aging. 2015;36(1):e547541–543. . https://doi.org/10.1016/j.neurobiolaging.2014.08.022

Article  CAS  Google Scholar 

Sun L, Hu CY, Shi XH, et al. Trans-ethnical shift of the risk genotype in the CETP I405V with longevity: a Chinese case-control study and meta-analysis. PLoS ONE. 2013;8(8):e72537. https://doi.org/10.1371/journal.pone.0072537.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson W, Harris SE, Collins P, Starr JM, Whalley LJ, Deary IJ. No association of CETP genotype with cognitive function or age-related cognitive change. Neurosci Lett. 2007;420(2):189–92. https://doi.org/10.1016/j.neulet.2007.05.013.

Article  CAS  PubMed  Google Scholar 

Qureischie H, Heun R, Popp J, et al. Association of CETP polymorphisms with the risk of vascular dementia and white matter lesions. J Neural Transm (Vienna). 2009;116(4):467–72. https://doi.org/10.1007/s00702-008-0180-y.